Commentary & Perspectives
Clinical Guidelines

Breaking Down Barriers to Biosimilar Access

With new approvals for its denosumab biosimilars, Biocon Biologics is working to close gaps in access across Europe. Blake Leitch shares how education, collaboration, and regulatory innovation can accelerate adoption and benefit more patients.

  • November 26, 2025

  • 7 min

Share

6 Key Takeaways

  • 1

    Biosimilars have been in Europe for 20 years.

  • 2

    Biocon's denosumab biosimilars focus on access and affordability.

  • 3

    Various countries use policies to promote biosimilar adoption.

  • 4

    The EMA aims to streamline the biosimilar approval process.

  • 5

    Biocon's portfolio includes oncology and diabetes therapies.

  • 6

    Collaboration with healthcare systems is essential for biosimilar integration.

Related Content

Targeting the Untouchables: Covalent Peptides That Target Elusive Transcription Factors

Researchers have developed a new way to create covalent peptide inhibitors of transcription factors – proteins once considered “undruggable.”

  • June 27, 2025

  • 9 min
Rethinking the Role of Lymph Nodes in Prostate Cancer: A study from Mount Sinai

In this study, Ash Tewari, MD and additional authors at Mount Sinai suggest re-evaluating the common practice of removing lymph nodes during prostate cancer surgery, as it can be risky and may not provide therapeutic benefits.

  • by

  • August 2, 2024

  • 1 min
Single Cell Multiomics and Mechanical Minds

A towering wall of data stands between humankind and a revolution in our understanding of biological systems – but advanced omics, AI, and machine learning can help knock it down

  • October 29, 2021

  • 7 min